Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.40 |
| ▸ | BACE1 | P56817 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121326 | 0.84 | NR1H2 (0.41) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL2113831 | 0.84 | NR1H2 (0.41) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL2113457 | 0.84 | EPHX2 (0.38) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL4652861 | 0.84 | EPHX2 (0.38) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL4651411 | 0.84 | NR1H2 (0.41) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL4651408 | 0.84 | NR1H2 (0.41) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL4652641 | 0.84 | EPHX2 (0.38) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL4651792 | 0.81 | EPHX2 (0.37) | CHRM1MEN1ALDH1A1KMT2AEPHX2 | |
| SCHEMBL4651696 | 0.81 | KCNA5 (0.40) | CHRM1MEN1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL4651793 | 0.81 | EPHX2 (0.37) | CHRM1MEN1ALDH1A1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | CHRM1 4467/4885MEN1 3470/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.